Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)

NCT07275723 is registered in ClinicalTrials.gov with Shanghai Shengdi Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07275723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07275723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)
Lead sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 14, 2025
Completion date
June 9, 2026
Enrollment
309 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

for contrast-enhanced magnetic resonance imaging (mri) of abnormal vascular lesions in body regions excluding the central nervous system (cns)